DUBLIN – Onxeo SA is picking up a new, clinical-stage approach to tackling cancer for a minimal outlay. The company is acquiring fellow French firm, DNA Therapeutics SA, for just €1.7 million (US$1.85 million) in stock initially, plus a second payment of €1 million in stock, to be triggered by the start of a phase II trial of DNA Therapeutics' lead drug candidate DT01. Most of the deal value is back-end-loaded.